1

2

3

4

5
Van Der, Geest Ronald, Stoffels Paul, Groen Cornelis, Jochmans Dirk Edward Désiré: Combination of cytochome p¿450? dependent protease inhibitors. Tibotec Pharmaceuticals, Van Der, Geest Ronald, Stoffels Paul, Groen Cornelis, Jochmans Dirk Edward Désiré, DAELEMANS Frank, June 19, 2003: WO/2003/049746

The present invention relates to a method for improving the pharmacokinetics of hexahydrofuro[2,3-b]furanyl containing HIV protease inhibitors comprising administering to a human in need thereof a combination of a therapeutically effective amount of a hexahydrofuro[2,3-b]furanyl containing HIV prote ...


6
Jochmans Dirk Edward Désiré, Wigerinck Piet Tom Bert Paul: Treating hiv infection, wherein hiv has a k65r mutation. Tibotec Pharmaceuticals, Jochmans Dirk Edward Désiré, Wigerinck Piet Tom Bert Paul, WANTE Dirk, August 9, 2007: WO/2007/088214

Nucleotide-competing reverse transcriptase inhibitors (NcRTI) bind to the active site of HIV reverse transcriptase (RT) in competition with the next incoming nucleotide. To further investigate the impact of RT inhibitor resistance mutations on the activity of NcRTIs, the susceptibility of > 6000 rec ...


7
Jochmans Dirk Edward Désiré, Wigerinck Piet Tom Bert Paul: Screening method for hiv rt inhibitors. Tibotec Pharmaceuticals, Jochmans Dirk Edward Désiré, Wigerinck Piet Tom Bert Paul, WANTE Dirk, August 10, 2006: WO/2006/082249

The present invention is directed to methods for identifying a specific class of inhibitors of HIV reverse transcriptase that act differently from known reverse transcriptase inhibitors. In particular, the invention is based on identifying inhibitors which have higher inhibitory activity in presence ...


8
Jochmans Dirk Edward Désiré, Wigerinck Piet Tom Bert Paul: Screening method for competitive hiv rt inhibitors. Tibotec Pharmaceuticals, Jochmans Dirk Edward Désiré, Wigerinck Piet Tom Bert Paul, WANTE Dirk, August 10, 2006: WO/2006/082250

A method for identifying a new class of nucleotide competitive RT inhibitors comprising: a) providing test compounds that are other than nucleoside triphosphates ; b) subjecting test compounds to a wild- type HIV virus replication test in cells; c) subjecting test compounds to a NNRTI resistant HIV ...


9

10